LivaNova Reports Q3 Revenue of $393.1 Million, Raises 2026 Guidance
LivaNova reported Q3 revenue of $393.1 million, up 9.9% year over year on a reported basis and 10.0% on a constant-currency basis, with adjusted diluted EPS of $1.23. It raised 2026 revenue-growth guidance to 9%–10% and adjusted diluted EPS guidance to $4.40–$4.50, up $0.10 at the midpoint.
LivaNova reported third-quarter 2026 revenue of $393.1 million, representing a 9.9% increase on a reported basis and 10.0% on a constant-currency basis compared to the prior-year period. The company achieved an adjusted diluted earnings per share of $1.23 for the quarter. Driven by these results, LivaNova raised its full-year 2026 revenue growth guidance to a range of 9% to 10% and increased its adjusted diluted earnings per share guidance by $0.10 at the midpoint to a range of $4.40 to $4.50. Additionally, the company reached an operational milestone with the launch of a new oxygenator manufacturing line to address customer demand.
The company also noted that the American Medical Association has established new Category I CPT codes for its proximal hypoglossal nerve stimulation therapy, effective January 1, 2028, and recently published 36-month results from its CORE-VNS study.